- Home
- MYSE vs OSRH Comparison
MYSE vs OSRH Comparison
Compare MYSE & OSRH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MYSE | OSRH |
|---|---|---|
| Founded | 2014 | N/A |
| Country | United States | United States |
| Employees | 11 | 21 |
| Industry | Telecommunications Equipment | |
| Sector | Telecommunications | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.2M | 11.7M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | MYSE | OSRH |
|---|---|---|
| Price | $1.85 | $0.58 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 6.0M | ★ 14.7M |
| Earning Date | 05-13-2026 | 05-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $9.30 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.31 | $0.38 |
| 52 Week High | $5.77 | $1.79 |
Technical Indicators
Market Signals| Indicator | MYSE | OSRH |
|---|---|---|
| Relative Strength Index (RSI) | 44.16 | 48.81 |
| Support Level | $1.64 | $0.47 |
| Resistance Level | $2.07 | $0.76 |
| Average True Range (ATR) | 0.24 | 0.12 |
| MACD | -0.09 | -0.01 |
| Stochastic Oscillator | 13.24 | 31.37 |
Price Performance
Historical ComparisonAbout MYSE Myseum Inc.
Myseum.AI Inc is an integrate proprietary privacy-first artificial intelligence (AI) and social media technology company. The Company is developing privacy-first agentic localized AI agents to assist in managing personal media such as photos, videos and messages, while maintaining privacy.
About OSRH OSR Holdings Inc.
OSR Holdings Inc is a healthcare company dedicated to healthcare outcomes and improving the quality of life for people and their families. It builds and develops a robust portfolio of potentially transformative therapies and healthcare solutions. The business of the company includes developing oral immunotherapies for the treatment of cancer, developing design-augmented biologics for age-related and other degenerative diseases, and neurovascular intervention medical device and systems distribution in Korea.